Fulgent Genetics Inc. (NASDAQ:FLGT) went down by -3.65% from its latest closing price compared to the recent 1-year high of $189.89. The company’s stock price has collected -5.23% of loss in the last five trading sessions. The Wall Street Journal reported on 04/05/21 that The Pandemic Year’s Top Stock-Fund Managers
Is It Worth Investing in Fulgent Genetics Inc. (NASDAQ :FLGT) Right Now?
Fulgent Genetics Inc. (NASDAQ:FLGT) scored a price-to-earnings ratio above its average ratio, recording 11.08 x from its present earnings ratio. Plus, the 36-month beta value for FLGT is at 1.62. Opinions of the stock are interesting as 2 analysts out of 4 who provided ratings for Fulgent Genetics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $107.00, which is -$3.07 below the current price. FLGT currently public float of 14.29M and currently shorts hold a 32.09% ratio of that float. Today, the average trading volume of FLGT was 2.07M shares.
FLGT’s Market Performance
FLGT stocks went down by -5.23% for the week, with a monthly jump of 0.79% and a quarterly performance of 56.95%, while its annual performance rate touched 875.58%. The volatility ratio for the week stands at 7.32% while the volatility levels for the past 30 days are set at 11.65% for Fulgent Genetics Inc.. The simple moving average for the period of the last 20 days is -9.11% for FLGT stocks with a simple moving average of 64.43% for the last 200 days.
Analysts’ Opinion of FLGT
Many brokerage firms have already submitted their reports for FLGT stocks, with Credit Suisse repeating the rating for FLGT by listing it as a “Underperform.” The predicted price for FLGT in the upcoming period, according to Credit Suisse is $40 based on the research report published on January 08th of the current year 2021.
Oppenheimer gave a rating of “Outperform” to FLGT, setting the target price at $75 in the report published on August 20th of the previous year.
FLGT Trading at -17.14% from the 50-Day Moving Average
After a stumble in the market that brought FLGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.99% of loss for the given period.
Volatility was left at 11.65%, however, over the last 30 days, the volatility rate increased by 7.32%, as shares sank -1.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.42% upper at present.
During the last 5 trading sessions, FLGT fell by -5.23%, which changed the moving average for the period of 200-days by +456.64% in comparison to the 20-day moving average, which settled at $102.32. In addition, Fulgent Genetics Inc. saw 78.64% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at FLGT starting from Xie Jian, who sale 3,000 shares at the price of $104.10 back on Mar 15. After this action, Xie Jian now owns 342,476 shares of Fulgent Genetics Inc., valued at $312,300 using the latest closing price.
Xie Jian, the Chief Operating Officer of Fulgent Genetics Inc., sale 62,000 shares at $102.65 during a trade that took place back on Mar 09, which means that Xie Jian is holding 345,476 shares at $6,364,219 based on the most recent closing price.
Stock Fundamentals for FLGT
Current profitability levels for the company are sitting at:
- +68.80 for the present operating margin
- +78.70 for the gross margin
The net margin for Fulgent Genetics Inc. stands at +51.85. The total capital return value is set at 86.52, while invested capital returns managed to touch 66.77. Equity return is now at value 92.70, with 75.70 for asset returns.
Based on Fulgent Genetics Inc. (FLGT), the company’s capital structure generated 2.78 points at debt to equity in total, while total debt to capital is 2.71. Total debt to assets is 2.25, with long-term debt to equity ratio resting at 0.10. Finally, the long-term debt to capital ratio is 0.10.
When we switch over and look at the enterprise to sales, we see a ratio of 2.30, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 3.99 and the total asset turnover is 1.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.02.